Novartis Healthcare has launched the Sequadra inhaler for the treatment of COPD.
Novartis Healthcare Private Ltd (NHPL) has launched Sequadra Inhaler (indacaterol/glycopyrronium) 110mcg/50mcg, a fixed dose combination of two bronchodilating active ingredients, indacaterol maleate, a long-acting beta2-adrenergic agonist (LABA) and glycopyrronium bromide, a long-acting anticholinergic (LAMA), for the treatment of COPD.
“NHPL is working hard to optimize this important treatment to Indian patients in a timely way”, said Jawed Zia, country president, Novartis India. “Once daily indacaterol/glycopyrronium combination reduces risk of annual rate of exacerbations by 31% compared to the current standard of care (twice-daily salmeterol + fluticasone combination) in patients with moderate-to-severe chronic obstructive pulmonary disease”
Addressing the media, Prof Claus Vogelmeier, Professor of Medicine and Head of Pulmonary Division, Marburg University Hospital, Germany said, “Indacaterol/Glycopyrronium combination will offer these patients a much greater improvement in lung function and health related quality of life. This new therapy will change the management of COPD to the benefit of patients”.
This was reinforced by Dr Ashok Mahashur, Consultant Chest Physician, P.D. Hinduja National Hospital and Medical Research Centre Mumbai, who stated, “Good to know that combination of indacaterol/glycopyrronium has been launched in India. Based on robust clinical data I feel this combination will be an effective bronchodilator and would reduce exacerbations in COPD patients”.